Applied Biosystems, Qiagen Ink PCR Licensing Deal
Applied Biosystems has granted a license to Qiagen under an expanded PCR license program that Applied Biosystems launched in June, the companies announced this week.
ABI's expanded program includes patents for real-time PCR and other PCR-related technologies not licensed under its previous PCR licensing program. Specifically, the program includes a license to foundational patents, the TaqMan assay, and the Dye-Intercalation assay method.
Financial terms of the arrangement were not disclosed.